The effect of interpleural and intravenous morphine on pain after video-assisted thoracoscopic surgery

Comparison of interpleural versus intravenous morphine for pain relief after video-assisted thoracoscopic Surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107046942N1

Enrollment

Registered

2011-07-21

Start date

2010-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Two different analgesic methods after VATS. Supplementary factors related to causes of morbidity and mortality classified elsewhere

Interventions

Intervention 1: At the end of VATS, eligible patients in control group will receive a single bolus of 0.1 mg/kg of morphine intravenously. Intervention 2: At the end of VATS, eligible patients in int

Treatment - Drugs

At the end of VATS, eligible patients in control group will receive a single bolus of 0.1 mg/kg of morphine intravenously

At the end of VATS, eligible patients in intervention group will receive a single bolus of 0.1 mg/kg of morphine interpleurally

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: ASA Class 1& 2, Age more than or equal 18, Weight more than or equal 40 kg, no limitations in terms of sex, height, surgery duration, type of surgical procedure, number and location of chest tubes. Exclusion criteria: Opium/alcohol addiction, drug abuse, mental retardation, psychological disorders, severe pleural adhesions and fibrosis, bronchopleural fistula, severe empyema, ASA class more than or equal 3, opioid consumption prior to surgery, inability to clamp chest tubes after surgery

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain severity after VATS. Timepoint: every one hour during the first postoperative 8 hours. Method of measurement: Visual analoge scale, supplemental analgesic consumption.	—

Secondary

Measure	Time frame
Mean arterial pressure. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: NIBP.;Heart rate. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: ECG.;SPO2. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: pulse oxymeter.;Side effects (nausea, vomiting,pruritus, respiratory depression). Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: observation and question.;Sedation score. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: Ramsay sedation scale.	—

Measure

Time frame

Mean arterial pressure. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: NIBP.;Heart rate. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: ECG.;SPO2. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: pulse oxymeter.;Side effects (nausea, vomiting,pruritus, respiratory depression). Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: observation and question.;Sedation score. Timepoint: every one hour during first postoperatve 8 hours. Method of measurement: Ramsay sedation scale.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Tahereh Parsa

National Research Institute of Tuberculosis & Lung Disease

tparsa849@yahoo.com+98 21 2610 9644

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026